Analysis of immune response in WT1 immunotherapy for malignant gliomas
Project/Area Number |
21791358
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Single-year Grants |
Research Field |
Cerebral neurosurgery
|
Research Institution | Osaka University |
Principal Investigator |
CHIBA Yasuyoshi Osaka University, 大学院・医学系研究科, 特任研究員 (90533795)
|
Project Period (FY) |
2009 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 悪性グリオーマ / WT1ペプチドワクチン療法 / 免疫療法 / 腫瘍浸潤リンパ球 / 免疫逃避 / テモゾロミド / 制御性T細胞 / HLA class1 / Wilm's Tumor 1 (WT1) / 腫瘍浸潤Tリンパ球 / HLA class 1 / WT1 / 細胞障害性T細胞 |
Research Abstract |
In this study, we tried to comprehend the immune accelerating or suppressive responses in patients' brain tumor tissues treated with WT1 peptide vaccination for malignant gliomas. And more, we considered whether the addition of WT1 peptide vaccination to temozolomide therapy, as an alternative treatment strategy for malignant gliomas, is feasible. The comparison between before and after WT1 peptide vaccination in brain tumor tissue showed the immune escape of tumor tissue. Temozolomide therapy did not significantly affect the frequency of WT1-specific CTLs, suggesting that the combination with WT1 peptide vaccination may be possible.
|
Report
(3 results)
Research Products
(16 results)
-
[Journal Article] Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.2010
Author(s)
Chiba Y, Hashimoto N, Tsuboi A, Oka Y, Murao A, Kinoshita M, Kagawa N, Oji Y, Hosen N, Nishida S, Sugiyama H, Yoshimine T.
-
Journal Title
Jpn J Clin Oncol. 40(5)
Pages: 395-403
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-